High brain serotonin levels in migraine between attacks:A 5-HT<sub>4</sub> receptor binding PET study by Deen, Marie et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
High brain serotonin levels in migraine between attacks
Deen, Marie; Hansen, Hanne D.; Hougaard, Anders; Nørgaard, Martin; Eiberg, Hans; Lehel,
Szabolcs; Ashina, Messoud; Knudsen, Gitte M
Published in:
NeuroImage: Clinical
DOI:
10.1016/j.nicl.2018.01.016
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Deen, M., Hansen, H. D., Hougaard, A., Nørgaard, M., Eiberg, H., Lehel, S., ... Knudsen, G. M. (2018). High
brain serotonin levels in migraine between attacks: A 5-HT4 receptor binding PET study. NeuroImage: Clinical,18, 97-102. https://doi.org/10.1016/j.nicl.2018.01.016
Download date: 03. Feb. 2020
Contents lists available at ScienceDirect
NeuroImage: Clinical
journal homepage: www.elsevier.com/locate/ynicl
High brain serotonin levels in migraine between attacks: A 5-HT4 receptor
binding PET study
Marie Deena,b,c,f,g, Hanne D. Hansenb,g, Anders Hougaarda,f, Martin Nørgaardb,c,g, Hans Eibergd,
Szabolcs Lehele, Messoud Ashinaa,c,f,1, Gitte M. Knudsenb,c,g,⁎,1
a Danish Headache Center, Department of Neurology, Rigshospitalet, DK-2600 Glostrup, Denmark
bNeurobiology Research Unit and NeuroPharm, Department of Neurology, Rigshospitalet, DK-2100 Copenhagen, Denmark
c Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark
d Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark
e PET- and Cyclotron Unit, Rigshospitalet, DK-2100 Copenhagen, Denmark
fDepartment of Neurology, Rigshospitalet, DK-2100 Copenhagen, Denmark
g Center for Experimental Medicine Neuropharmacology, Department of Neurology, Rigshospitalet, DK-2100 Copenhagen, Denmark
A R T I C L E I N F O
Keywords:
Headache
Pain
Neuroimaging
Brain
Serotonergic mechanisms
A B S T R A C T
Migraine has been hypothesized to be a syndrome of chronic low serotonin (5-HT) levels, but investigations of
brain 5-HT levels have given equivocal results. Here, we used positron emission tomography (PET) imaging of
the 5-HT4 receptor as a proxy for brain 5-HT levels. Given that the 5-HT4 receptor is inversely related to brain 5-
HT levels, we hypothesized that between attacks migraine patients would have higher 5-HT4 receptor binding
compared to controls. Eighteen migraine patients without aura (migraine free>48 h), and 16 age- and sex-
matched controls underwent PET scans after injection of [11C]SB207145, a speciﬁc 5-HT4 receptor radioligand.
An investigator blinded to group calculated a neocortical mean [11C]SB207145 binding potential (BPND). Three
migraine patients reported a migraine attack within 48 h after the scan and were excluded from the primary
analysis. Comparing 15 migraine patients and 16 controls, we found that migraine patients have signiﬁcantly
lower neocortical 5-HT4 receptor binding than controls (0.60 ± 0.09 vs. 0.67 ± 0.05, p= .024), corrected for
5-HTTLPR genotype, sex and age. We found no association between 5-HT4 receptor binding and attack fre-
quency, years with migraine or time since last migraine attack. Our ﬁnding of lower 5-HT4 receptor binding in
migraine patients is suggestive of higher brain 5-HT levels. This is in contrast with the current belief that mi-
graine is associated with low brain 5-HT levels. High brain 5-HT levels may represent a trait of the migraine
brain or it could be a consequence of migraine attacks.
1. Introduction
Migraine is a highly debilitating and socioeconomically costly
neurological disorder, aﬀecting 16% of the population worldwide
(Olesen et al., 2012; Steiner et al., 2013). Despite intensive research
during the past several decades, the neurobiological basis and patho-
physiology of migraine remains largely unknown. Serotonin (5-hydro-
xytryptamine, 5-HT) has been directly implicated in the pathophy-
siology of migraine (Hamel, 2007) and studies on plasma and urinary
levels of 5-HT and its main metabolite, 5-hydoxyindoleacetic acid (5-
HIAA) suggest that between their migraine attacks, patients have de-
creased levels of plasma 5-HT (Ferrari et al., 1989; Sicuteri et al., 1961).
Accordingly, although plasma levels of 5-HT do not necessarily reﬂect
brain 5-HT levels, migraine has been considered a syndrome of
chronically low brain 5-HT levels. Several studies have attempted to
assess brain 5-HT levels in migraine patients, but results have been
equivocal, showing both higher and lower levels compared to controls
(Deen et al., 2017a). We here use a novel neuroimaging method to
investigate if migraine is a syndrome associated with low 5-HT brain
levels.
The 5-HT4 receptor, one of 14 5-HT receptors, is inversely related to
central serotonergic tonus and can thus be used as an indirect bio-
marker of brain 5-HT levels. In rats, brain 5-HT4 receptor binding de-
creased after 14 days of selective 5-HT reuptake inhibitor (SSRI)
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administration (Licht et al., 2009). In humans, carriers of the short al-
lele of the 5-HT transporter (5-HTT) gene, which is associated with
relatively increased synaptic 5-HT levels, had lower neocortical 5-HT4
receptor binding compared to carriers of the long allele (Fisher et al.,
2012). Furthermore, the ﬁnal support for the 5-HT4 receptor being in-
versely related to brain 5-HT levels, came from a study showing that
three weeks of SSRI intervention led to a signiﬁcant decrease in brain 5-
HT4 receptor binding in humans (Haahr et al., 2014).
Here we investigated diﬀerences in brain 5-HT levels between mi-
graine patients without aura and controls using PET imaging of the 5-
HT4 receptor as an in vivo biomarker of brain 5-HT levels. According to
existing beliefs, we hypothesized that migraine patients had higher 5-
HT4 receptor binding compared to controls.
2. Materials and methods
2.1. Subjects
Participants were recruited through a Danish website for recruit-
ment of volunteers to health research and from a local database. All
patients fulﬁlled the following inclusion criteria: 1) 18–65 years old, 2)
a veriﬁed diagnosis of migraine without aura according to the
International Headache Society Criteria (HCC IHS, 2013). 3) at least
one migraine attack every other month but less than ﬁve migraine days
per month, 4) self-reported previous eﬀect of treatment of migraine
attacks with sumatriptan (a 5-HT1B/1D receptor agonist drug). The last
criterion was applied, since the subjects were also included in a study
investigating the 5-HT1B receptor (Deen et al., 2017b). A standardized
interview of all patients was conducted at screening including the fol-
lowing items: duration of disease (years), duration of attack when un-
treated (hours), migraine days pr. month, frequency of attack (number
per month), maximum pain intensity of untreated headache as mea-
sured with the Numerical Rating Scale (NRS) (number 0–10), intake of
acute pain medication including triptans (days per month), and date of
their last migraine attack. Inclusion criteria for age- and sex-matched
controls included: 1) no history of migraine including probable mi-
graine and no ﬁrst-degree relatives with migraine. For all participants,
the following exclusion criteria were applied: 1) a history of any other
primary headache (except tension-type headache<5 days per month),
2) psychiatric, cerebro- or cardiovascular disease, 3) contraindications
for magnetic resonance imaging (MRI), 4) pregnancy or nursing, 5)
daily intake of medication including migraine prophylaxis.
All subjects reported to be headache free on the day of their PET
scan, and no medication intake was allowed for the last 24 h prior to the
scan. All migraine patients were migraine free for at least 48 h prior to
the PET scan. In addition, to ensure that all included subjects were truly
between two migraine attacks, headache diaries were obtained from all
patients for 48 h after the scan. All included participants had a normal
physical and neurological examination and unremarkable brain MRI.
All participants ﬁlled out the major depression inventory (MDI) on the
day of the PET scan.
The study was approved by the Ethics Committee of The Region of
Copenhagen (H-6-2014-057). In accordance with the Declaration of
Helsinki of 1964, with later revisions, all participants gave written
consent after detailed oral and written information about the study.
2.2. PET and MR imaging
Synthesis of the radioligand, [11C]SB207145, was performed using
an automated radiosynthesis system as previously described (Marner
et al., 2009). An intravenous bolus injection of the radioligand was
given over 20 s, followed by 120-minute dynamic data acquisition with
a high-resolution research tomography (HRRT) PET scanner (CTI/Sie-
mens, Knoxville, TN, USA). To minimize head movement, all subjects
had their head stabilized in a specialized head holder. The scans were
reconstructed into 38 frames (6×5, 10×15, 4× 30, 5×120,
5×300, and 8×600 s) using a 3D-OSEM-PSF algorithm (16 subsets,
10 iterations) with TXTV based attenuation correction (image matrix,
256× 256×207; voxel size, 1.22×1.22×1.22mm), as previously
described (Hong et al., 2007; Keller et al., 2013; Sureau et al., 2008). T1
and T2 weighted MRI scans used for co-registration were acquired for
each subject using a Siemens Prisma 3T scanner (Siemens, Erlangen,
Germany) with a 64-channel head coil.
2.3. Quantiﬁcation of 5-HT4 receptor binding
Single-subject PET images were corrected for intra-scan movement
by aligning the frames 10–38 to a reference frame (frame 26) using a
scaled least-squares cost function in AIR 5.2.5. Co-registration and
alignment of PET images to the corresponding T1-weighted MRI image
was done using SPM8. Regions of interest (ROIs) were automatically
delineated on each subject's MRI using PVElab software (www.nru.dk)
as previously described (Svarer et al., 2005). Accurate co-registration
and ROI placement were conﬁrmed by visual inspection for each sub-
ject, across all planes. Time activity curves (TAC) and grey matter vo-
lumes for each ROI were then extracted.
The Simpliﬁed Reference Tissue Model (SRTM) was applied to cal-
culate the non-displaceable binding potential (BPND) of [11C]SB207145.
This model has previously been validated for quantiﬁcation of [11C]
SB207145 in the human brain (Marner et al., 2009). Cerebellum (ex-
cluding vermis) was used as a reference region since it has a negligible
density of 5-HT4 receptors (Ganz et al., 2017; Marner et al., 2009).
Kinetic modeling was performed in MATLAB R2013a (8.1.0.604) 64 bit
(Mathworks Inc., MA) using an in-house script and the person per-
forming the kinetic modeling was blinded to group status (migraine
patient or control). Parametric 5-HT4 receptor binding images for voxel
based analysis were generated using PETSurfer (http://surfer.nmr.mgh.
harvard.edu, version 6.0), as previously described (Greve et al., 2014).
In summary, a combined volumetric and surface registration algorithm
was used to normalize each single-subject structural T1 to Montreal
Neurological Institute (MNI) space (Postelnicu et al., 2009). After ap-
plication to the co-registered PET-images, these were then volume-
smoothed with a 6-mm full-width half-maximum 3D Gaussian kernel.
The Multilinear Reference Tissue Model 2 (MRTM2), using cerebellum
as reference region and high-binding regions (putamen, pallidum and
caudate) for estimation of k2′, was applied to estimate voxel-level
BPNDs.
2.4. Genotyping
Participants were genotyped for the tri-allelic 5-HT transporter-
linked polymorphic region (5-HTTLPR) polymorphism. Brieﬂy, geno-
typing was performed by PCR ampliﬁcation from forward primer
5′-TAATGTCCCTACTGCAGCCC-3′ and reverse primer 5′-GGGACTGAG
CTGGACAACC-3′. The fragments were then digested by the restriction
enzyme MspI and separated by gel electrophoresis. Participants were
categorized into two groups: 1. Carriers of the short allele (S-carriers) or
the long LG allele (LG-carriers). 2. Homozygotes of the long LA allele (LA-
homozygotes). This dichotomization was based on a previous study
showing that carriers of the low-expressing alleles, S and LG have lower
neocortical 5-HT4 receptor binding compared to homozygotes of the
high-expressing allele, LA (Fisher et al., 2012).
2.5. Experimental design and statistical analysis
This study was an observational, cross-sectional study comparing
interictal migraine without aura patients (> 48 hour migraine free
before and after the scan) with sex- and age matched controls. Sample
size was based on a previous study showing that n=15 is suﬃcient to
detect a 15% diﬀerence between groups with a power of 0.80 in very
large brain regions (> 50 cm3), such as e.g. neocortex (Marner et al.,
2010). Diﬀerences between groups in demographics, genotypes and
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PET variables were evaluated using two-sample t-tests.
To evaluate diﬀerences in brain 5-HT levels between migraine pa-
tients and controls we used the BPND of a large neocortical region as a
proxy of central serotonergic tonus. The neocortical BPND was chosen,
since previous studies investigating brain 5-HT levels in migraine
mostly focused on cortical regions (for review see (Deen et al., 2017a)).
The cortical brain regions receive numerous serotonergic projections
from the raphe nuclei and 5-HT plays an important role in the mod-
ulation of cortical activity (Celada et al., 2013). Additionally, the re-
lationship between the 5-HTTLPR genotype and 5-HT4 receptor binding
is most pronounced in neocortex (Fisher et al., 2012).
The mean neocortical [11C]SB207145 BPND was calculated based on
11 neocortical brain regions (occipital cortex, orbitofrontal cortex, su-
perior, medial and inferior frontal gyri, insula, superior, medial and
inferior temporal gyri, sensory motor cortex and parietal cortex) by
volume weighting grey matter segmented brain region BPND's:
−
= − ∗
Neocortical 5 HT receptor binding
Σ[5 HT BP (region ) volume(region )]/[Σ (volume(region ))]
4
4 ND x x x
As our primary investigation, a general linear model including
neocortical BPND as the primary dependent variable and group status
(patients vs. controls) as the predictive variable was then used to model
eﬀects of group on neocortical 5-HT4 receptor binding. To this model,
5-HTTLPR-status (S or LG carriers vs. LA homozygotes), sex and age
were added as covariates, since all are known to aﬀect neocortical 5-
HT4 receptor binding (Fisher et al., 2012; Madsen et al., 2015, 2011a).
All subjects received tracer doses (injected mass of SB207145 <
0.024 μg/kg) obviating the inclusion of injected mass a covariate
(Madsen et al., 2011b). Eﬀects of interaction between group and gen-
otype were evaluated and excluded unless statistically signiﬁcant. To
detect any regional (including subcortical) speciﬁc group diﬀerences in
5-HT4 receptor binding, whole brain voxel-wise multiple regression was
performed using the same linear model as in the primary analysis. Only
voxels (sized 1×1×1mm) with an average BPND > 0.3 were eval-
uated within a whole brain mask. In addition, associations between
measures of clinical severity (attack frequency, years with migraine and
time since last migraine attack) and neocortical 5-HT4 receptor binding
were evaluated in the patient group only using a general linear model
including 5-HTTLPR-status, age and sex as co-variates.
Statistical tests were carried out using R Studio 3.2.3 and SPM8. We
ensured that model assumptions were met by examination of quantile-
quantile plots, distribution of the residuals, and predicted values
plotted against residuals. In the ROI analyses, the signiﬁcance threshold
was set at p < .05 (two-tailed). In the voxel based analysis, a p-value
threshold of p < .001 at voxel level was used. To correct for multiple
comparisons only clusters at p < .05 corrected using the family wise
error rate (FWE) were assumed signiﬁcant. All other p-values are re-
ported without correction for multiple comparison.
3. Results
3.1. Demographics and migraine characteristics
Out of the 18 migraine patients who completed the study, three
reported to have a migraine attack within 48 h after the PET scan. These
were excluded from the primary analysis. Sixteen controls completed
the study. One migraine patient (subject 15) was scanned for 90 instead
of 120min, because she felt anxious in the scanner. To ensure that this
patient did not aﬀect our results, we conducted the primary analysis
both with and without this patient. Thus, data from 15 migraine pa-
tients and 16 controls were included in the primary analysis.
A summary of demographics and PET variables are presented in
Table 1. Clinical data of the migraine group is shown in Table 2. The
regional distribution of the tracer was in concordance with previous
studies with lowest binding in neocortex and highest binding in
striatum. We found no diﬀerences in grey matter volume or MDI score
between the two groups and no interaction between group and geno-
type.
3.2. Diﬀerences in neocortical binding
We found that migraine patients had signiﬁcant lower neocortical
[11C]SB207145 binding compared to controls (0.60 ± 0.09
(mean ± SD) vs. 0.67 ± 0.05 (mean ± SD), p= .024) (Fig. 1) after
adjustment for covariates. This diﬀerence remained after excluding
subject 15 (0.63 ± 0.06 vs. 0.68 ± 0.05, p= .038). Post hoc ex-
plorative analysis of the ROIs included in the neocortical region showed
that the low binding was most pronounced within the orbitofrontal
cortex (p= .009), insula (p= .018), superior temporal gyrus
(p= .019), parietal cortex (p= .026), medial and inferior temporal
gyrus (p= .032), and superior frontal gyrus (p= .040). The voxel-
based analysis revealed no signiﬁcant clusters after rigorous FWE cor-
rection.
3.3. Associations with migraine characteristics
We found no associations between neocortical 5-HT4 receptor
binding and attack frequency (slope estimate −0.017, CI:
[−0.081;0.047], p= .56), years with migraine (slope estimate 0.003,
CI: [−0.007;0.012], p= .53), or days since last attack (slope estimate
0.002, CI: [−0.003;0.007], p= .40).
Table 1
Demographics and PET variables.
Patients Controls p-Valuea
Number of subjects (men/women) 15 (2/13) 16 (3/13)
Genotype (LA homozygote/S or LG
carrier)
6/9 6/10
Age (years) 29.6 ± 10.2 28.9 ± 10.2 .85
BMI (kg/m2) 22.6 ± 1.7 23.9 ± 4.8 .33
Major depression inventory 7.87 ± 7.6 7.13 ± 4.8 .75
Injected radioactivity (MBq) 584 ± 16 591 ± 19 .34
Speciﬁc radioactivity (GBq/μmol) 567 ± 282 486 ± 217 .38
[11C]SB injected mass per kg (μg/
kg)
0.008 ± 0.006 0.008 ± 0.005 .90
[11C]SB cerebellum AUC/speciﬁc
radioactivity (GBq/μmol)
31.1 ± 23 32.6 ± 21 .85
Continuous variables are presented as mean ± SD.
a Two-sample t-test.
Table 2
Migraine history.
Subject Migraine
history
(years)
Attack
frequency
(n/month)
Time since last migraine
attack (days)
1 8 2 17
2 7 2 12
3 21 3 11
4 25 1 22
5 15 2 15
6 20 1 31
7 19 1 19
8 8 0.5 50
9 17 2 15
10 7 1 29
11 6 3 10
12 2 2 7
13 36 4 4
14 16 3 5
15 10 2 13
Median (range) 15 (2–36) 2 (0.5–4) 15 (4–50)
M. Deen et al. NeuroImage: Clinical 18 (2018) 97–102
99
4. Discussion
The key ﬁnding of this study is that between attacks, migraine pa-
tients have lower 5-HT4 receptor binding within neocortex compared to
controls. Our post hoc ROI analysis showed that this diﬀerence was
most pronounced within the orbitofrontal, parietal, temporal and in-
sular cortices, but no signiﬁcant clusters were found when using a
whole brain voxel-based analysis. This discrepancy is probably due to
the conservative statistical method applied to the voxel-based analysis
(p-value threshold of p < .001 at voxel level, and correction for mul-
tiple comparisons using FWE) and due to the large whole-brain search
volume. The latter was applied in order to detect any possible sub-
cortical diﬀerences. Further, the detected diﬀerence between migraine
patients and healthy controls was rather small, around 10%. This is,
however, in line with previous studies ﬁnding signiﬁcant diﬀerences in
5-HT4 receptor binding between groups diﬀering with regards to in-
tervention, genes or disease. Thus, a 5.2% decrease was found after
3 weeks of ﬂuoxetine intervention (Haahr et al., 2014), BDNF met-
carriers were shown to have 7% higher neocortical binding relative to
val/val-carriers, whereas 5-HTTLPR S-carriers had 7% lower binding
compared to LL homozygotes (Fisher et al., 2015, 2012), and lastly, in
Alzheimer's patients, PIB-positive patients had 13% higher binding
compared to PIB-negative patients (Madsen et al., 2011c).
Although an acute increase in brain 5-HT levels does not aﬀect [11C]
SB207145 BPND (Marner et al., 2010), we took great care to ensure that
all included patients were scanned during an attack-free interval (mi-
graine free 48 h before and after scan) to exclude possible eﬀects of
attack related changes in brain 5-HT levels on 5-HT4 receptor binding.
However, inclusion of the three subjects who reported to have a mi-
graine attack within 48 after the scan did not change our results
(p= .024). Furthermore, to reduce the possibility of variability in [11C]
SB207145 binding due to diurnal 5-HT variations, we scanned all pa-
tients at the same time of the day (± 1 h). Since we found no diﬀerence
in grey matter volume between patients and controls within neocortex
this is likewise not thought to aﬀect the magnitude of 5-HT4 receptor
binding. Lastly, the low 5-HT4 receptor binding could reﬂect changes in
aﬃnity of the 5-HT4 receptor in migraine patients. However, in colliculi
neurons desensitization of the 5-HT4 receptor is caused by a loss of
binding sites after continued 5-HT exposure (Ansanay et al., 1996).
Thus, we interpret our ﬁndings of low [11C]SB207145 binding to reﬂect
low neocortical density of the 5-HT4 receptor in migraine patients.
The low neocortical 5-HT4 receptor density in patients could be
explained by repeated surges of 5-HT during migraine attacks – causing
an on average higher brain 5-HT level with subsequent downregulation
of the cerebral 5-HT4 receptor. In support of this, our post hoc analysis
identiﬁed lower 5-HT4 receptor binding in several regions implicated in
migraine attacks; e.g. functional neuroimaging studies reported in-
creased activation of insula, the prefrontal cortex and the temporal lobe
during attacks compared to the attack free interval (Afridi et al., 2005;
Weiller et al., 1995). Moreover, both insula and the orbitofrontal cortex
are involved in pain modulation (Tracey, 2008). However, we found no
direct association between 5-HT4 receptor binding and migraine history
(years), attack frequency (number per month) or days since the last
migraine attack. It would be interesting to investigate whether duration
of attack combined with frequency – as a measure of hours with pain pr.
month – is associated with 5-HT4 receptor binding, but this analysis
would have required a detailed, prospective headache diary. In addi-
tion, we cannot rule out a possible relationship between migraine se-
verity and brain 5-HT levels in high frequency or chronic migraine.
Future studies should include this patient group to investigate further
whether the low 5-HT4 receptor density is a consequence of repeating
migraine attacks.
Alternatively, the low neocortical 5-HT4 receptor density may re-
ﬂect high brain 5-HT levels in migraine patients in the attack free in-
terval. This interpretation challenges the longstanding belief that mi-
graine patients have low brain 5-HT levels between attacks. To date,
electrophysiological studies have provided the most substantial evi-
dence for the 5-HT deﬁciency hypothesis (Coppola et al., 2009). Mi-
graine patients between attacks showed a lack of habituation of visual
evoked potentials (VEP) (Afra et al., 2000) and an increased intensity
dependence of auditory evoked potentials (AEP) (Wang et al., 1996),
both thought to reﬂect low brain 5-HT levels (Schoenen, 1996; Wutzler
et al., 2008). However, most of these studies were unblinded and did
not report time to the next migraine attack. In addition, the ﬁndings
were not reproduced in other studies (Omland et al., 2013; Sand, 2013).
In the current study, all included migraine patients had been migraine
free for 48 h before and after the scan and all data analyses were con-
ducted by an investigator who was blinded to diagnoses and clinical
data.
In addition to electrophysiological studies, some PET studies have
suggested that brain 5-HT levels are low in migraine patients, but the
results have been inconsistent. In a 5-HT1A-receptor PET neuroimaging
study, higher cortical BPND in migraine patients compared to controls
was interpreted as reﬂecting low brain 5-HT levels (Lothe et al., 2008).
However, the 5-HT1A receptor radioligand, [18F]MPPF, is not convin-
cingly sensitive to endogenous 5-HT levels in humans (Paterson et al.,
2010). One study reported a higher brain 5-HT synthesis capacity in
migraine patients without aura when using α-[11 C]methyl-L-trypto-
phan as a surrogate marker of brain 5-HT synthesis capacity (Chugani
et al., 1999). This was interpreted as being consistent with a high 5-HT
turnover and thus, low brain 5-HT levels. Interestingly, in another study
using the same method, ﬁndings of a low cortical 5-HT synthesis ca-
pacity in migraine patients was likewise interpreted as reﬂecting low
cortical 5-HT levels (Sakai et al., 2008). Taking the limitations of these
studies (Chugani et al., 1999; Sakai et al., 2008) into account (the re-
liability of α-[11 C]methyl-L-tryptophan as a surrogate marker of brain
5-HT synthesis capacity has been questioned (Shoaf et al., 2000)), one
might speculate whether a low 5-HT synthesis capacity could indeed
reﬂect high 5-HT levels – as found in the current study – due to a ne-
gative feedback regulation on 5-HT synthesis. On the other hand, a high
synthesis capacity may potentially lead to high 5-HT levels. In further
support of our ﬁndings, high brain 5-HT levels in migraine patients
between attacks may, at least partly, explain, why selective 5-HT re-
uptake inhibitors are not eﬃcient as migraine prophylaxis (Banzi et al.,
2015).
Fig. 1. Migraine patients have lower neocortical 5-HT4 receptor binding than controls
(0.60 ± 0.09 vs. 0.67 ± 0.05, p= .024) after adjusting for covariates (5-HTTLPR status,
age, and sex). Black bars indicate mean ± SD. The diﬀerence remained after exclusion of
subject 15 (the patient with the lowest BPND) (0.63 ± 0.06 vs. 0.68 ± 0.05, p= .038).
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4.1. Possible migraine-inducing mechanisms of serotonin
Serotonergic agents such as m-chlorophenylpiperazine (m-CPP)
(Leone et al., 2000), reserpine (Curzon et al., 1969), and fenﬂuramine
(Sicuteri et al., 1976) induce migraine attacks more frequently in mi-
graine patients than in controls, and most likely via increasing brain 5-
HT levels (Panconesi and Sicuteri, 1997). Since our data suggest the
presence of increased brain 5-HT levels in migraine patients between
attacks, we propose that migraine patients could be more susceptible to
additional acute increases in 5-HT, which lead to migraine induction.
5-HT has generally been considered an inhibiting agent of pain and
is one of the major neurotransmitters of the descending pain-inhibition
pathway (Stamford, 1995). In vitro, 5-HT exerts an antinociceptive
eﬀect in the trigeminal system (Kilinc et al., 2016) and in healthy an-
imals 5-HT inhibits pain (Viguier et al., 2013). However, recent pre-
clinical studies have shown that 5-HT may be involved in pain facil-
itation as well (Bardin, 2011). In 5-HT depleted rats, the acute pain
reaction was intact but pain behavior in the second phase after formalin
injection was attenuated. In addition, in persistent pain models 5-HT
depleted rats exhibited a decrease in thermal hyperalgesia and me-
chanical allodynia (Wei et al., 2010). These pathophysiological-de-
pendent properties of 5-HT may be due to the complex role of the
diﬀerent 5-HT receptor subtypes: The 5-HT1 and 5-HT3 receptors are
generally considered antinociceptive, whereas the 5-HT2A and the 5-
HT7 receptors are considered pronociceptive (Viguier et al., 2013).
Thus, 5-HT may be both pro- and antinociceptive depending on re-
ceptor type, aﬃnity and concentration (Sommer, 2006). Interestingly,
low density of the antinociceptive 5-HT1B receptor was recently found
in pain modulating regions in migraine patients between attacks (Deen
et al., 2017b). In light of our present ﬁndings we therefore speculate
that the pathophysiology of migraine includes an imbalance in the pain
modulating system caused by high interictal brain 5-HT levels and
changes in expression of diﬀerent 5-HT receptor subtypes, resulting in
loss of inhibition and enhancement of pain facilitation.
4.2. Limitations
Even though several studies have corroborated the inverse re-
lationship between 5-HT4 receptor binding and brain 5-HT levels
(Haahr et al., 2014; Licht et al., 2009), the method used in the present
study is still an indirect measure of brain 5-HT levels. In addition, we
cannot rule out that the eﬀect of migraine status on the 5-HT4 receptor
is speciﬁc for this receptor, and not due to changes in brain 5-HT levels.
5. Conclusions
Migraine patients have low neocortical 5-HT4 receptor binding.
Since pharmacological studies of 5-HT4 receptor binding suggest an
inverse relationship with brain 5-HT levels, this most likely indicates
higher brain 5-HT levels in migraine patients compared to controls. Our
results, therefore, support the involvement of the serotonergic system in
migraine pathophysiology, but are in contrast with the current hy-
pothesis that migraine is a syndrome of low brain 5-HT levels. Future
studies must explore whether our observation is due to high brain 5-HT
levels between attacks, predisposing to migraine, or is the result of
recurring migraine attacks with surges of 5-HT.
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